A Phase III Comparison of CHOP Versus m-BACOD Versus ProMACE-CytaBOM Versus MACOP-B in Patients with Intermediate or High-Grade Non-Hodgkin's Lymphoma

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

H Gustafson (Tardif);S Yao;B Goldman;K Lee;C Spier;M LeBlanc;L Rimsza;JR Cernan;TM Habermann;BK Link;MJ Mauer;SL Slager;D Persky;T Miller;RI Fisher;C Ambrosone;M Briehl American Journal of Hematology 89(6):639-645;

PMid: PMID24633940 | PMC number: PMC4137041

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Natural history of central nervous system (CNS) relapse in patients with aggressive non-hodgkin's lymphoma: a 20 year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group [PMID19047289]

SH Bernstein;JM Unger;M LeBlanc;JW Friedberg;TP Miller;RI Fisher Journal of Clinical Oncology 27(1):114-119

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Central nervous system (CNS) relapse in agressive non-Hodgkin's lymphoma; does CNS prophylaxis work?

SH Bernstein;J Unger;M LeBlanc;RI Fisher Blood 110(11):#520

The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic and clinical features

RM Braziel;DA Arber;ML Slovak;ML Gulley;C Spier;C Kjeldsberg;J Unger;TP Miller;R Tubbs;C Leith;RI Fisher;TM Grogan Blood 97(12):3713-3720

Burkitt-like lymphoma: a distinctive morphology and phenotype with poor prognosis

R Braziel;D Arber;T Miller;R Fisher;T Grogan Modern Pathology 12(1):132A(#771)

BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study.

JN Winter;J Andersen;JC Reed;S Krajewski;D Variakojis;KD Bauer;RI Fisher;LI Gordon;MM Oken;S Jiang;D Jeffries;P Domer Blood 91(4):1391-1398

Treatment of grey zone lymphomas

RI Fisher Annals of Oncology 9(5):S121-S123

Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.

RI Fisher Cancer Chemotherapy and Pharmacology 40(Suppl):S42-46

Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.

JN Winter;J Andersen;D Variakojis;LI Gordon;RI Fisher;MM Oken;RS Neiman;S Jiang;KD Bauer Blood 88(10):3919-3925

A Southwest Oncology Group (SWOG) analysis of the anaplastic large cell lymphoma (ALCL) entities in the revised European American lymphoma (REAL) classification.

T Grogan;C Kjeldsberg;R Tubbs;S Dahlberg;R Braziel;C Foucar;C Leith;C Spier;E Gaynor;T Miller;R Fisher International Academy of Pathology Book of Abstracts :111A(#644)

Prognostic significance of the Ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphoma: A prospective Southwest Oncology Group (SWOG) trial.

TP Miller;TM Grogan;S Dahlberg;CM Spier;RM Braziel;PM Banks;K Foucar;CR Kjeldsberg;N Levy;BN Nathwani;B Schnitzer;RR Tubbs;ER Gaynor;RI Fisher Blood 83(6):1460-1466

African americans treated on SWOG NHL studies: Similar incidence, received dose intensity and outcome to caucasian patients.

S Dahlberg;RI Fisher;CA Coltman ASCO 13:370(#1251)

Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: An analysis of SWOG-8516 (INT 0067) - the national high priority lymphoma study - a randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B.

ER Gaynor;S Dahlberg;RI Fisher ASCO 13:370(#1250)

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the national high-priority lymphoma study

RI Fisher;ER Gaynor;S Dahlberg;MM Oken;TM Grogan;EM Mize;JH Glick;CA Coltman;TP Miller Annals of Oncology 5(Suppl.2):S91-S95

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

RI Fisher;ER Gaynor;S Dahlberg;MM Oken;TM Grogan;EM Mize;JH Glick;CA Coltman Jr;TP Miller NEJM 328:1002-1006

A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: Preliminary results of SWOG-8516 (Intergroup 0067).

RI Fisher;E Gaynor;S Dahlberg;EM Mize;M Oken ASCO 11:315(#1067), oral, plenary session (Proceedings of ASCO, Vol. 11, March 1992, p.315)

Southwest Oncology Group clinical trials for intermediate andhigh-grade non-hodgkin's lymphomas.

RI Fisher;TP Miller;BW Dana;SE Jones;S Dahlberg;C Coltman, Jr Seminars in Hematology 24(2):21-25